References
- Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164-2167. https://doi.org/10.1001/jama.295.18.2164
- Olson E, Wintheiser G, Wolfe KM, Droessler J, Silberstein PT. Epidemiology of thyroid cancer: A review of the national cancer database, 2000-2013. Cureus. 2019;11:e4127.
- Shah JP. Thyroid carcinoma: epidemiology, histology, and diagnosis. Clin Adv Hematol Oncol. 2015;13:3-6.
- Cancer Genome Atlas Research N. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676-690. https://doi.org/10.1016/j.cell.2014.09.050
- Chakravarty D, Santos E, Ryder M, Knauf J, Liao X, West B, et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. Journal of Clinical Investigation. 2011;121:4700-4711. https://doi.org/10.1172/JCI46382
- Pozdeyev N, Gay LM, Sokol ES, Hartmaier R, Deaver KE, Davis S, et al. Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. Clin Cancer Res. 2018;24:3059-3068. https://doi.org/10.1158/1078-0432.CCR-18-0373
- Ganly I, Ricarte Filho J, Eng S, Ghossein R, Morris LG, Liang Y, et al. Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. J Clin Endocrinol Metab. 2013;98:E962-972. https://doi.org/10.1210/jc.2012-3539
- Xing M. BRAF V600E mutation and papillary thyroid cancer. JAMA. 2013;310:535. https://doi.org/10.1001/jama.2013.8592
- Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol. 2015;33:42-50.
- Yoo SK, Song YS, Lee EK, Hwang J, Kim HH, Jung G, et al. Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer. Nat Commun. 2019;10:2764. https://doi.org/10.1038/s41467-019-10680-5
- Yip DT, Hassan M, Pazaitou-Panayiotou K, Ruan DT, Gawande AA, Gaz RD, et al. Preoperative basal calcitonin and tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thyroid carcinoma. Surgery. 2011;150:1168-1177. https://doi.org/10.1016/j.surg.2011.09.043
- Passos I, Stefanidou E, Meditskou-Eythymiadou S, Mironidou-Tzouveleki M, Manaki V, Magra V, et al. A Review of the significance in measuring preoperative and postoperative carcinoembryonic antigen (CEA) values in patients with medullary thyroid carcinoma (MTC). Medicina (Kaunas); 2021. p.57.
- Kurzrock R, Atkins J, Wheler J, Fu S, Naing A, Busaidy N, et al. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Ann Oncol. 2013;24:2256-2261. https://doi.org/10.1093/annonc/mdt177
- Hadoux J, Pacini F, Tuttle RM, Schlumberger M. Management of advanced medullary thyroid cancer. Lancet Diabetes Endocrinol. 2016;4:64-71. https://doi.org/10.1016/S2213-8587(15)00337-X
- Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: A 10-year follow-up study. J Clin Endocrinol Metab. 2008;93:682-687. https://doi.org/10.1210/jc.2007-1714
- Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts NJ, et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab. 2013;98:E364-369. https://doi.org/10.1210/jc.2012-2703
- Grubbs EG, Ng PK, Bui J, Busaidy NL, Chen K, Lee JE, et al. RET fusion as a novel driver of medullary thyroid carcinoma. J Clin Endocrinol Metab. 2015;100:788-793. https://doi.org/10.1210/jc.2014-4153
- Ji JH, Oh YL, Hong M, Yun JW, Lee HW, Kim D, et al. Identification of driving ALK fusion genes and genomic landscape of medullary thyroid cancer. PLoS Genet. 2015;11:e1005467. https://doi.org/10.1371/journal.pgen.1005467
- Schlumberger M, Leboulleux S. Current practice in patients with differentiated thyroid cancer. Nat Rev Endocrinol. 2021;17:176-188. https://doi.org/10.1038/s41574-020-00448-z
- Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, et al. Phase I clinical trials in 56 patients with thyroid cancer: The M. D. Anderson cancer center experience. J Clin Endocrinol Metab. 2009;94:4423-4432. https://doi.org/10.1210/jc.2009-0743
- Klein M, Vignaud JM, Hennequin V, Toussaint B, Bresler L, Plenat F, et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2001;86:656-658. https://doi.org/10.1210/jc.86.2.656
- Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. Lancet. 2014;384:319-328. https://doi.org/10.1016/S0140-6736(14)60421-9
- Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621-630. https://doi.org/10.1056/NEJMoa1406470
- Cabanillas ME, de Souza JA, Geyer S, Wirth LJ, Menefee ME, Liu SV, et al. Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: Results of a multicenter phase II international thyroid oncology group trial. J Clin Oncol. 2017;35:3315-3321. https://doi.org/10.1200/JCO.2017.73.0226
- Brose MS, Robinson B, Sherman SI, Krajewska J, Lin CC, Vaisman F, et al. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22:1126-1138. https://doi.org/10.1016/S1470-2045(21)00332-6
- Foote RL, Molina JR, Kasperbauer JL, Lloyd RV, McIver B, Morris JC, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid. 2011;21:25-30. https://doi.org/10.1089/thy.2010.0220
- Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36:7-13.
- Iyer PC, Dadu R, Ferrarotto R, Busaidy NL, Habra MA, Zafereo M, et al. Real-world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma. Thyroid. 2018;28:79-87. https://doi.org/10.1089/thy.2017.0285
- Wells SA, Jr., Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial. J Clin Oncol. 2012;30:134-141.
- Elisei R, Schlumberger MJ, Muller SP, Schoffski P, Brose MS, Shah MH, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31:3639-3646. https://doi.org/10.1200/JCO.2012.48.4659
- Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med. 2020;383:825-835. https://doi.org/10.1056/NEJMoa2005651
- Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021;9:491-501. https://doi.org/10.1016/S2213-8587(21)00120-0
- Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15:731-747. https://doi.org/10.1038/s41571-018-0113-0
- Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378:731-739. https://doi.org/10.1056/NEJMoa1714448
- Cabanillas ME, Drilon A, Farago AF, Brose MS, McDermott R, Sohal D, et al. 1916P Larotrectinib treatment of advanced TRK fusion thyroid cancer. Annals of Oncology. 2020;31:S1086.
- Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21:271-282. https://doi.org/10.1016/s1470-2045(19)30691-6
- Shah MH, Wei L, Wirth LJ, Daniels GA, Souza JAD, Timmers CD, et al. Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma. Journal of Clinical Oncology. 2017;35:6022-6022. https://doi.org/10.1200/jco.2017.35.15_suppl.6022
- Locati LD, Piovesan A, Durante C, Bregni M, Castagna MG, Zovato S, et al. Real-world efficacy and safety of lenvatinib: Data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. Eur J Cancer. 2019;118:35-40. https://doi.org/10.1016/j.ejca.2019.05.031
- Ho A, Grewal R, Leboeuf R, Sherman E, Pfister D, Deandreis D, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. New England Journal of Medicine. 2013;368:623-632. https://doi.org/10.1056/NEJMoa1209288
- Rothenberg S, Daniels G, Wirth L. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with Dabrafenib-response. Clinical Cancer Research. 2015;21:5640-5641. https://doi.org/10.1158/1078-0432.CCR-15-2298
- Jaber T, Waguespack S, Cabanillas M, Elbanan M, Vu T, Dadu R, et al. Targeted therapy in advanced thyroid cancer to resensitize tumors to radioactive iodine. Journal of Clinical Endocrinology and Metabolism. 2018;103:3698-3705. https://doi.org/10.1210/jc.2018-00612
- Groussin L, Clerc J, Huillard O. Larotrectinib-enhanced radioactive iodine uptake in advanced thyroid cancer. N Engl J Med. 2020;383:1686-1687. https://doi.org/10.1056/NEJMc2023094
- Buffet C, Wassermann J, Hecht F, Leenhardt L, Dupuy C, Groussin L, et al. Redifferentiation of radioiodine-refractory thyroid cancers. Endocr Relat Cancer. 2020;27:R113-R132. https://doi.org/10.1530/ERC-19-0491
- Capdevila J, Wirth LJ, Ernst T, Ponce Aix S, Lin CC, Ramlau R, et al. PD-1 blockade in anaplastic thyroid carcinoma. J Clin Oncol. 2020;38:2620-2627. https://doi.org/10.1200/JCO.19.02727
- Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer. 2018;6:68. https://doi.org/10.1186/s40425-018-0378-y
- Cabanillas ME, Dadu R, Ferrarotto R, Liu S, Fellman BM, Gross ND, et al. Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC). Journal of Clinical Oncology. 2020;38:6514-6514. https://doi.org/10.1200/jco.2020.38.15_suppl.6514
- Solomon BJ, Tan L, Lin JJ, Wong SQ, Hollizeck S, Ebata K, et al. RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies. J Thorac Oncol. 2020;15:541-549. https://doi.org/10.1016/j.jtho.2020.01.006
- Ou SI, Cui J, Schrock AB, Goldberg ME, Zhu VW, Albacker L, et al. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib. Lung Cancer. 2017;108:228-231. https://doi.org/10.1016/j.lungcan.2017.04.003